For the first time, leading U.S. scientists have united to build a coordinated national research effort focused exclusively ...

Sichun Yang, PhD, a member of Case CCC's Molecular Oncology Program, and Alberto Montero, MD, a Developmental Therapeutics Program member, are looking for patient advocates for a follow-up study to ...

Based on WHO classification, Breast carcinomas have varying histomorphologies and each subtype has its own translational importance. Invasive lobular ...

While researchers work to improve lobular breast cancer screening, innovative treatments are improving outcomes for patients with the condition, which is diagnosed in more than 40,000 Americans each ...

Invasive lobular carcinoma accounts for about 10% of breast cancer diagnoses. Its incidence is increasing at the rate of 2.8% annually -- more than triple that of other breast cancers combined. This ...

Rates of one type of breast cancer — invasive lobular carcinoma — have been rising in the United States more than three times faster than those of all other breast cancers combined over the past ...

Genomic alterations (GAs) associated with durability of benefit from trastuzumab deruxtecan (T-DXd), trastuzumab emtansine (T-DM1) and sacituzumab govitecan (SG) in metastatic breast cancer (MBC).

Lobular breast cancer rates increased 2.8 percent per year over the past decade, compared with a 0.8 percent annual increase for all other breast cancers. Lobular breast cancer grows in a linear ...

Nearly a year ago, I wrote in these pages that lobular breast cancer must no longer be the “forgotten cancer”.